HbA1c:Review of Standardisation and Quality Management

doi:10.3969/j.issn.1673-8640.2013.10.001

检验医学 ›› 2013, Vol. 28 ›› Issue (10): 867-872.DOI: 10.3969/j.issn.1673-8640.2013.10.001

• 专家论坛 • 下一篇

HbA_1c:Review of Standardisation and Quality Management

CasWeykamp

Queen Beatrix Hospital，Winterswijk Netherlands

收稿日期:2013-08-12 出版日期:2013-10-30 发布日期:2013-10-29
作者简介:CasWeykamp博士，现任荷兰贝娅特丽克丝女王医院的临床化学家、荷兰室间质评计划负责人、IFCCHbA_1c参考实验室网络联络官、IFCCHbA_1c整合计划成员、美国AACC一致性计划研发组主席、NGSP执行委员会成员、上海市临床检验中心学术顾问，是国际知名的糖化血红蛋白研究专家，致力于建立HbA_1c参考体系、推进HbA_1c检测的全球标准化。

Received:2013-08-12 Online:2013-10-30 Published:2013-10-29

摘要/Abstract

摘要：

糖化血红蛋白(HbA_1c)目前被认为是患者长期血糖控制和监测的金标准。2010年起，相继被美国糖尿病学会(ADA)、国际糖尿病联盟(IDF)、美国临床内分泌医师学会(AACE)、欧洲糖尿病研究学会(EASD)和世界卫生组织(WHO)等纳入糖尿病的诊断标准。在临床实验室中检测HbA_1c主要有阳离子交换色谱、亲和色谱、免疫比浊、电泳、酶化学和即时检验(POCT)等方法，检测结果间存在较大差异。自1993年起，国际临床化学联盟(IFCC)成立的HbA_1c标准化工作组和美国AACC建立的国家糖化血红蛋白标准化计划(NGSP)一起，致力于实现HbA_1c检测的标准化。本文全面介绍了HbA_1c的标准化、质量管理以及未来发展。

Key words: Glycated hemoglobin A_1c, Diabetes, Standardisation, Quality management

中图分类号:

R446.1

Cas Weykamp. HbA_1c:Review of Standardisation and Quality Management[J]. 检验医学, 2013, 28(10): 867-872.

参考文献

[1] World Health Organization. WHO diabetes media centre[EB/OL]. (2013-03-01) [2013-08-10]. http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
[2] American Diabetes Association. Economic costs of diabetes in the U.S. in 2007[J]. Diabetes Care,2008,31(6):1271.
[3] The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus[J]. N Eng J Med,1993,329(14):977-986.
[4] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)[J]. Lancet,1998,352(9131):837-853.
[5] White NH, Sun W, Cleary PA, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents[J]. Diabetes,2010,59(5):1244-1253.
[6] Weykamp C, John WG, Mosca A. A review of the challenge in measuring hemoglobin A1c[J]. J Diabetes Sci Technol,2009,3(3):439-445.
[7] Jaisson S, Leroy N, Meurice J, et al. First evaluation of Capillarys 2 Flex Piercing^○R (Sebia) as a new analyzer for HbA1c assay by capillary electrophoresis[J]. Clin Chem lab Med,2012,50(10):1769-1775.
[8] Mallia AK, Hermanson GT, Krohn RI, et al. Preparation and use of a boronic acid affinity support for separation and quantisation of glycosylated haemoglobin[J]. Anal Lett,1981,14:649-661.
[9] John WG, Gray MR, Bates DL, et al. Enzyme immunoassay-a new technique for estimating haemoglobin A1c[J]. Clin Chem,1993,39(4):663-666.
[10] Liu L, Hood S, Wang Y, et al. Direct enzymatic assay for % HbA1c in human whole blood samples[J]. Clin Biochem,2008,41(7-8):576-83.
[11] Greg Miller W, Myers GL, Lou Gantzer M, et al. Roadmap for harmonization of clinical laboratory measurement procedures[J]. Clin Chem,2011,57(8):1108-1117.
[12] Little RR, Rohlfing CL, Wiedmeyer HM, et al. The national glycohemoglobin standardization program: a five-year progress report[J]. Clin Chem,2001,47(11):1985-1992.
[13] Shima K, Endo J, Oimomi M, et al. Interlaboratory differences in GHb measurement in Japan, the fifth report of the GHb standardisation committee, the Japan Diabetes Society[J]. J Jap Diab Soc,1998,41:317-333.
[14] Jeppsson JO, Jerntorp P, Sundkvist G, et al. Measurement of haemoglobin A1c by a new liquid-chromatographic assay: methodology, clinical utility and relation to glucose tolerance evaluated[J]. Clin Chem,1986,32(10):1867-1872.
[15] Jeppsson JO, Kobold U, Barr J, et al. Approved IFCC reference method for the measurement of HbA1c in human blood[J]. Clin Chem Lab Med,2002,40(1):78-89.
[16] Weykamp C, John WG, Mosca A, et al. The IFCC reference measurement system for HbA1c: a 6 year progress report[J]. Clin Chem,2008,54(2):240-248.
[17] Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1c measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine and International Diabetes Federation[J]. Diabetes Care,2007,30(9): 2399-2400.
[18] American Diabetes Association. Standards of medical care in diabetes-2011[J]. Diabetes Care,2011,34(Suppl 1):S11-S61.
[19] American Diabetes Association. Standards of medical care in diabetes-2010[J]. Diabetes Care,2010,33(Suppl 1):S11-S61.
[20] Little RR, Rohlfing CL, Tennill AL, et al. Effects of sample storage conditions on glycated haemoglobin measurement: evaluation of five different high performance liquid chromatography methods[J]. Diabetes Technol Ther,2007,9(1):36-42.
[21] Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus[J]. Clin Chem,2011,57(6):e1-e47.
[22] Little RR, Rohlfing CL, Sacks DB. Status of hemoglobin HbA1c measurement and goals for improvement: from chaos to order for improving diabetes care[J]. Clin Chem,2011,57(2):205-214.
[23] Lenters-Westra E, Slingerland RJ. Six of eight haemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria[J]. Clin Chem,2010,56(1):44-52.

HbA_1c:Review of Standardisation and Quality Management

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	高子康, 陈晶. 基于外周血淋巴细胞亚群特征构建抑郁障碍患者预后列线图预测模型[J]. 检验医学, 2025, 40(12): 1146-1152.
[2]	王田, 张赟, 白毅, 翟卫斌, 赵海. PIV、SII和NPAR在肝硬化腹水患者自发性细菌性腹膜炎诊断中的价值[J]. 检验医学, 2025, 40(12): 1153-1158.
[3]	黄婷, 徐燕, 史庆星, 彭蘡. miR-944和MARCH7 mRNA在非小细胞肺癌患者预后评估中的价值[J]. 检验医学, 2025, 40(12): 1159-1164.
[4]	李明红, 闵翠丽, 郭庆波, 马璐娟. 血清25（OH）D、SAA对自身免疫性肝炎患者免疫抑制剂治疗应答的预测价值[J]. 检验医学, 2025, 40(12): 1165-1170.
[5]	甄迪, 贾宾, 孟宪一. 溃疡性结肠炎患者血清sPD-1、sTWEAK水平在病情监测和预后评估中的价值[J]. 检验医学, 2025, 40(12): 1171-1176.
[6]	赵依琳, 徐燕, 尹辉. 血清miR-145-5p、miR-200C-3p、miR-1290在甲状腺乳头状癌患者预后评估中的价值[J]. 检验医学, 2025, 40(12): 1177-1182.
[7]	李松, 向旭. 老年发热伴血小板减少综合征患者预后危险因素及其临床价值[J]. 检验医学, 2025, 40(12): 1183-1189.
[8]	常楠, 魏亚丽, 路其凤, 李钿, 侯婷婷, 李远, 朱梦羽, 沈亚娟. 基于血液分析仪参数构建急性早幼粒细胞白血病机器学习预警模型[J]. 检验医学, 2025, 40(12): 1190-1196.
[9]	蔡眉, 王佳余, 顾丹凤, 何佳亮, 周丽芳, 杨海鸥. 凝血、纤溶、生化指标在预测妊娠期静脉血栓栓塞中的价值[J]. 检验医学, 2025, 40(12): 1197-1202.
[10]	尹庆霞, 王茜平, 盛婷, 雷琴. 不同尿白蛋白排泄率糖尿病肾病患者肠道微生物群结构特征[J]. 检验医学, 2025, 40(12): 1216-1221.
[11]	高俊杰, 曹庆雪, 杨子善. Ⅰ型胶原氨基端延长肽量值溯源体系的建立和评价[J]. 检验医学, 2025, 40(12): 1222-1226.
[12]	包雯. 微卫星不稳定性检测在肿瘤诊疗中的应用进展[J]. 检验医学, 2025, 40(12): 1227-1231.
[13]	熊赢, 郭玮. 从通用到个性化：间接法建立参考区间的演进与前沿展望[J]. 检验医学, 2025, 40(11): 1035-1041.
[14]	陈燕勤, 范利娜, 杨大干. 6种间接法算法建立杭州地区成人胱抑素C参考区间一致性分析[J]. 检验医学, 2025, 40(11): 1047-1052.
[15]	刘春燕, 牛书敏, 邓朝晖, 梁梦洁, 张新. 间接法建立乌鲁木齐地区AFP、CEA、CA72-4和CA19-9参考区间[J]. 检验医学, 2025, 40(11): 1053-1058.